Dimitri Luz Felipe da Silva

Dimitri Luz Felipe da Silva

Auto-generated profile, based on publicly available information

Dimitri Luz Felipe da Silva

D.L.F. Silva, MD, MSc, University Santo Amaro, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2022 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
DSDimitri Luz Felipe da Silva
Dimitri Luz Felipe da Silva
ESElisa Nunes Secamilli
Elisa Nunes Secamilli
MBMariana Valbon Beleli
Mariana Valbon Beleli
JMJuliana Yumi Massuda
Juliana Yumi Massuda
AFAndrea F.E.C. Franca
Andrea F.E.C. Franca
RMRenata F. Magalhães
Renata F. Magalhães
Immunobiologicals are a reality in current clinical practice and have increasingly gained space in the inflammatory disease scenario, especially in dermatology, with approved drugs for psoriasis, atopic dermatitis, and hidradenitis suppurativa, in addition to many others undergoing study. It is important for dermatologists to have knowledge of the medications approved in Brazil, for the best management of dermatoses, in addition to the fact that they represent hope for improvement in patients with chronic diseases.

1 March 2021 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
DSDimitri Luz Felipe Silva
Dimitri Luz Felipe Silva
LGLuiz Gameiro
Luiz Gameiro
JMJuliana Yumi Massuda
Juliana Yumi Massuda
RMRenata Ferreira Magalhães
Renata Ferreira Magalhães
AFAndrea Fernandes Eloy da Costa França
Andrea Fernandes Eloy da Costa França

15 August 2025 in The Journal of Rheumatology
Verified
Journal Article
Closed access
DSDimitri Luz Felipe da Silva
Dimitri Luz Felipe da Silva
SSShikha Singla
Shikha Singla
PMPhilip J. Mease
Philip J. Mease
The interplay between metabolic health and autoimmune diseases such as psoriasis (PsO) and psoriatic arthritis (PsA) has garnered increasing attention. Obesity, a key feature of metabolic syndrome, exacerbates disease severity in these conditions, prompting the exploration of treatments addressing both the immune system and metabolism. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), primarily used for type 2 diabetes mellitus, have demonstrated benefits beyond glycemic control, including promoting weight loss, improving metabolic health, and potentially modulating immune responses. There is also a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist with similar and potentially superior capabilities; throughout this manuscript these will be collectively known as GLP-1RA. Recent studies also suggest that GLP-1RAs may help manage PsO and PsA in patients with obesity. These medications may offer dual benefits by reducing inflammation and addressing metabolic abnormalities like insulin resistance and hyperlipidemia. This article reports on a presentation given at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting underscoring the potential of GLP-1RAs as a therapeutic option, particularly for obese patients with PsO and PsA. Although promising, the evidence supporting GLP-1RAs for treating PsO and PsA remains limited, necessitating further clinical research to evaluate their safety and efficacy.

15 July 2023 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
GAGizem Ayan
Gizem Ayan
RCRoxana Coras
Roxana Coras
RGRachel Grynszpan
Rachel Grynszpan
SHSebastián Herrera
Sebastián Herrera
HJHannah Jethwa
Hannah Jethwa
FPFabian Proft
Fabian Proft
Young-GRAPPA (Y-GRAPPA) was introduced at the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting. Here we present the 1-year progress of Y-GRAPPA and future plans of this enthusiastic group of young clinicians and early career researchers interested in psoriasis and psoriatic arthritis.

1 October 2024 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
CSCLAUDIA GOLDENSTEIN SCHAINBERG
CLAUDIA GOLDENSTEIN SCHAINBERG
DSDimitri Luz Felipe da Silva
Dimitri Luz Felipe da Silva
ESEnrique R. R. Soriano
Enrique R. R. Soriano
LSLaura J. Savage
Laura J. Savage
PMPhilip J. Mease
Philip J. Mease
The 1st GRAPPA International Meeting on Psoriasis and Psoriatic Arthritis – 1° Encontro Internacional do GRAPPA Sobre Psoríase e Artrite Psoriásica was held on August 18-19, 2023, in São Paulo, Brazil, and marked a turning point in the management of psoriasis (PsO) and psoriatic arthritis (PsA) in our country. This was an international collaboration, between Brazilian rheumatologists and dermatologists and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), aiming to promote medical knowledge and particularly the optimal care and management of Brazilian patients with psoriatic disease (PsD).

18 July 2025 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
DSDimitri Luz F. Silva
Dimitri Luz F. Silva
RRRafael Rubinho
Rafael Rubinho
ADAriany Denofre
Ariany Denofre
Sandra AvilaSandra Avila
Sandra Avila
RMRenata Ferreira Magalhães
Renata Ferreira Magalhães
Artificial intelligence (AI) is increasingly gaining ground in dermatology, with studies reporting accuracy equal to or greater than dermatologists for the diagnosis of skin lesions from clinical and dermoscopic images.1 AI has been developed and improved constantly for dermatology, however, the focus has been much more on neoplastic diseases, due to their high prevalence and high morbidity. Describe the possible applications of AI in inflammatory dermatoses. Articles published between 2013 and 2023 in Medline and Lilacs were retrieved after applying the inclusion and exclusion criteria 19 articles were selected. From each selected article, the necessary information was extracted and with this data, the present review was written. The first studies on AI in dermatology focused on the diagnosis of neoplasms, especially melanoma, due to the ease of standardization of images, obtaining accuracy equivalent to that of a dermatologist in clinical and dermoscopic lesions. Actually, there are many studies on artificial intelligence in inflammatory dermatosis, such as psoriasis, helping to calculate the PASI, hidradenitis suppurativa, and atopic dematitis. The limitation of the study is that it is a literature review and because it is an innovative topic with a limited number of studies published in the literature. Considerable of what is published in the literature is in computer science journals, but it is possible to perceive that there is an important interest in the area and that artificial intelligence will advance to assist dermatologists.